About Prenosis
Prenosis is a biology-based technology company that develops precision medicine tools for critical acute care conditions. The company's mission is to empower clinicians to see patients differently by providing deep understanding of each patient's unique biology, enabling tailored treatments and improved outcomes. Prenosis leverages its Immunix precision medicine platform, which has created the world's largest biomarker-clinical dataset for infection in acute care, to develop and validate new diagnostic tools. The company's flagship product, the Sepsis ImmunoScore, is the first FDA-authorized AI diagnostic for sepsis. By integrating biomarkers and clinical data through machine learning, the Sepsis ImmunoScore evaluates a patient's risk of experiencing adverse outcomes within 24 hours. The diagnostic seamlessly integrates into hospital Electronic Health Records, enabling timely interventions that improve patient outcomes, enhance hospital quality metrics, and reduce costs. Prenosis serves health systems and hospitals, with direct EMR integration and an exclusive partnership with Roche Diagnostics for broader distribution. The company's Immunix platform simultaneously enables the development of new precision medicine tools while implementing them in real-time to improve patient care.
Mission & Story
Mission
To improve patient lives by tailoring healthcare to each patient's biology.
Clinical Focus
Medical conditions and clinical areas addressed by Prenosis.
Who It Serves
Milestones & Awards
Recent Milestones
Bobby Reddy Jr. named to TIME's 2025 TIME100 Health List (May 2025). Sepsis ImmunoScore named TIME Best Invention of 2024 (October 2024). New England Journal of Medicine study published (December 2024). FDA De Novo Authorization received for Sepsis ImmunoScore.
Awards & Recognition
TIME Best Invention of 2024 for Sepsis ImmunoScore. Bobby Reddy Jr. on TIME100 Health List 2025.
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.